Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis

Journal of Bone and Mineral Research

Volumn 24, Issue 9, 2009, Pages 1544-1551

  Delmas, Pierre D ^a   Munoz, Francoise ^a   Black, Dennis M ^b   Cosman, Felicia ^c   Boonen, Steven ^d   Watts, Nelson B ^e   Kendler, David ^f   Eriksen, Erik F ^g   Mesenbrink, Peter G ^g   Eastell, Richard ^h  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HELEN HAYES HOSPITAL   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF CINCINNATI   (United States)

^f Osteoporosis Research Centre   (Canada)

^g NOVARTIS PHARMA AG   (Switzerland)

^h NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bone turnover markers; Fracture; Osteoporosis; Procollagen type 1 amino terminal propeptide; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; IPRIFLAVONE; MEDROXYPROGESTERONE; PRASTERONE; PROCOLLAGEN C PROTEINASE; RALOXIFENE; TAMOXIFEN; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; BONE FRAGILITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG INFUSION; FEMALE; FOLLOW UP; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK REDUCTION; THERAPY EFFECT; TREATMENT RESPONSE; VERTEBRA FRACTURE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS; PEPTIDE FRAGMENTS; POSTMENOPAUSE; PROCOLLAGEN;

EID: 70449345629     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090310     Document Type: Article

References (47)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541. (Pubitemid 26411651)
2. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822. (Pubitemid 46698462)
3. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249. (Pubitemid 41094364)
4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082. (Pubitemid 29014065)
5. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352. (Pubitemid 29483192)
6. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
7. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R,Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
8. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91. (Pubitemid 30099515)
9. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
10. Coxon FP, Thompson K, Rogers MJ 2006 Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6:307-312. (Pubitemid 43670914)
11. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829-7834. (Pubitemid 43752866)
12. Rogers MJ 2003 New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643-2658. (Pubitemid 37456015)
13. Chen YT, Miller PD, Barrett-Connor E, Weiss TW, Sajjan SG, Siris ES 2007 An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 18:1287-1296. (Pubitemid 47300284)
14. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A 2005 Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194. (Pubitemid 40863806)
15. Meunier PJ, Boivin G 1997 Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone 21:373-377. (Pubitemid 27485304)
16. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289. (Pubitemid 34219441)
17. Delmas PD, Seeman E 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604. (Pubitemid 38393794)
18. Li J, Mashiba T, Burr DB 2001 Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281-286. (Pubitemid 33140938)
19. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10. (Pubitemid 33150990)
20. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261. (Pubitemid 39178892)
21. Delmas PD, Li Z, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337. (Pubitemid 38116748)
22. Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB 2006 Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 26:104-114. (Pubitemid 43082931)
23. Seeman E 2007 Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308-317.
24. Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890-899. (Pubitemid 38581135)
25. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526-1536. (Pubitemid 30484522)
26. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 11:76-82.
27. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258. (Pubitemid 41094365)
28. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930. (Pubitemid 34001005)
29. Eastell R, Barton I,Hannon RA, Chines A, Garnero P,Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056. (Pubitemid 37294942)
30. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD 2007 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: Review of statistical analysis. J Bone Miner Res 22:1656-1660. (Pubitemid 351235131)
31. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401. (Pubitemid 38787394)
32. Garnero P, Borel O, Delmas PD 2001 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702. (Pubitemid 32275813)
33. Glover S, Gall M, Schoenborn-Kellenberger O, Garnero P, Boonen S, Cauley J, Black DM, Delmas PD, Eastell R 2009 Establishing a reference range for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and USA. J Bone Miner Res 24:389-397.
34. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631-2637. (Pubitemid 44024629)
35. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661.
36. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: Oneyear results from the dosing intravenous administration study. Arthritis Rheum 54:1838-1846. (Pubitemid 43877933)
37. Miller PD 2003 Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert Opin Pharmacother 4:2253-2258. (Pubitemid 37541238)
38. Karsdal MA, Qvist P, Christiansen C, Tanko LB 2006 Optimising antiresorptive therapies in postmenopausal women: Why do we need to give due consideration to the degree of suppression? Drugs 66:1909-1918.
39. Seeman E, Delmas PD 2006 Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261. (Pubitemid 43788139)
40. Clarita V, Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak Cy 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301. (Pubitemid 40463979)
41. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89:349-353. (Pubitemid 46563912)
42. Lee P, van der Wall H, Seibel MJ 2007 Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with postmenopausal osteoporosis on alendronate therapy. J Endocrinol Invest 30:590-597. (Pubitemid 47577812)
43. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS 2008 An emerging pattern of subtrochanteric fractures: A long-term complication of alendronate therapy? Injury 39:224-231.
44. Lenart BA, Lorich DG, Lane JM 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306.
45. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16.
46. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809. (Pubitemid 350044800)
47. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351. (Pubitemid 38177616)